Why Clinical Trial Enrollment Sucks

Written By Kenny Kane

[audio mp3="https://pdcn.co/e/rss.art19.com/episodes/6f479c95-42aa-4509-b84e-eb601bd5df98.mp3?rss_browser=BAhJIgljdXJsBjoGRVQ%3D--435795d5c850773aaa4739d968bd77a1dfd6f301"][/audio] Why Clinical Trial Enrollment Sucks

My guest today is Dr. Selin Kurnaz, Founder and CEO of Massive Bio, a company that is as impressive as it sounds. Its mission is to solve one of the single most critical scathing holes in healthcare: the "last mile" of clinical trial enrollment. What does that mean? You'll find out during our conversation, and rightfully so; the explanation will further deepen your pre-existing disdain for "the system." Selin is a no-BS serial entrepreneur who defines herself as a "non-status-quo businesswoman." whose sole purpose is to ensure every cancer patient gets access to a clinical trial; because only 20% of all patients that qualify for a clinical trial never actually fully enroll in that trial. And that is not OK. All that and more on the show today, let's get started.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kenny Kane

Kenny Kane is an entrepreneur, writer, and nonprofit innovator with 15+ years of experience leading organizations at the intersection of business, technology, and social impact. He is the CEO of Firmspace, CEO of the Testicular Cancer Foundation, and CTO/co-founder of Gryt Health.

A co-founder of Stupid Cancer, Kenny has built national awareness campaigns and scaled teams across nonprofits, health tech, and real estate. As an author, he writes about leadership, resilience, and building mission-driven organizations.

Previous

[THROWBACK] The Heart of Healthcare with Mark Cuban
Next

HEALTH CARELESS // Stressbop, Snakes, and SCOTUS